COPD and Asthma affect nearly 10% of Earth's population, with COPD now listed as the 3rd leading cause of death worldwide. Yet advances in respiratory care management have not kept up pace. Late and inaccurate diagnosis of respiratory conditions drives billions in healthcare costs through exacerbations and hospitalisations, many of which are preventable.
Our vision is to transform COPD diagnostic pathways to drive efficiency and drastically improve patient care, through purposeful innovation grounded in cutting-edge science. Our mission is to become a global leader in respiratory diagnostics and care management
Diversity and inclusion are the heart of our culture, ensuring our team reflects the community we serve. We prioritise representation to advance equitable healthcare outcomes for all.
We aim to set the standard for sustainable medical device development targeting a Net Zero future. Our technologies are developed sustainably minimising single-use plastics.
A revolutionary first of its kind rapid, accurate, point-of-care diagnostic solution for COPD, delivered as a fully managed service.
Read MoreA remote patient monitoring solution powered by our N-Tidal digital biomarkers, enabling longitudinal assessment of respiratory health.
Read MorePatented, industry leading sensor that's over 10 years in the making, with clinical evidence that proves it's changing how we understand respiratory health
Automatically transmits breath data via built-in 4G connectivity to our cloud platform
Collected and analysed in our clinical trials are now driving our powerful AI diagnostic and monitoring algorithms
Facilitating targeted early intervention, preventing deterioration for people with COPD, asthma, and other respiratory conditions
TidalSense is committed to driving a fundamental shift in diagnostic pathways by creating value for patients, clinicians and healthcare systems.
Enhancing clinical practice with new respiratory insights and easy, operationally efficient and cost-effective respiratory diagnostic solutions.
Read moreBoosting Phase II & III clinical trials, and optimising therapeutic management of patients in the community.
Read more